There is a relationship between aging and hormonal issues that create a distinctive path for development of liver disease in menopausal women. There are growing numbers of menopausal women worldwide, therefore the effect of understanding of how menopause mediates liver disease is important as.

Menopause signifies a state of growing estrogen shortage, and this loss of estrogen in the setting of physiologic aging upsurges the likelihood of mitochondrial dysfunction, cellular senescence, decreasing immune responses to injury, and disarray in the balance between antioxidant formation and oxidative stress. There are numerous physiologic and biochemical changes in menopause that can affect the function of the liver and mediate the development of liver disease. The outcome of these changes can contribute to increased susceptibility to development of significant liver pathology, particularly nonalcoholic fatty liver disease and hepatocellular carcinoma, as well as accelerated progression of fibrosis in liver diseases. Understanding the unique nature of these mediating factors should raise suspicion for liver disease in perimenopausal and menopausal women and bid an occasion for execution of aggressive treatment measures so as to avoid progression of liver disease to cirrhosis, liver cancer and liver failure.

There are numerous physiologic and biochemical changes in menopause that can affect the function of the liver and mediate the development of liver disease. Menopause represents a state of growing estrogen deficiency, and this loss of estrogen in the setting of physiologic aging increases the likelihood of mitochondrial dysfunction, cellular senescence, declining immune responses to injury, and disarray in the balance between antioxidant formation and oxidative stress. The sum effect of these changes can contribute to increased susceptibility to development of significant liver pathology, particularly nonalcoholic fatty liver disease and hepatocellular carcinoma, as well as accelerated progression of fibrosis in liver diseases, as has been particularly demonstrated in hepatitis C virus liver disease. Recognition of the unique nature of these mediating factors should raise suspicion for liver disease in perimenopausal and menopausal women and offer an opportunity for implementation of aggressive treatment measures so as to avoid progression of liver disease to cirrhosis, liver cancer and liver failure.

The combination of age and hormonal factors exceptionally effects the growth and evolution of liver disease in postmenopausal women. There must be a discriminating suspicion for possible liver disease and early implementation of therapies to minimize the likelihood of progression to advanced liver disease, liver cancer, and liver-related death, with recognition of the numerous physiologic and biochemical changes that occur in menopause,.

World J Gastroenterol. 2015 Jul 7; 21(25): 7613–7620